BioNTech SE (BNTX)

NASDAQ: BNTX · IEX Real-Time Price · USD
-0.91 (-1.05%)
At close: Jul 19, 2024, 4:00 PM
+1.04 (1.22%)
After-hours: Jul 19, 2024, 7:29 PM EDT
Market Cap 20.32B
Revenue (ttm) 2.97B
Net Income (ttm) 122.83M
Shares Out 237.73M
EPS (ttm) 0.51
PE Ratio 167.57
Forward PE 7.04
Dividend n/a
Ex-Dividend Date n/a
Volume 359,681
Open 86.01
Previous Close 86.37
Day's Range 85.02 - 86.45
52-Week Range 78.02 - 125.83
Beta 0.23
Analysts Buy
Price Target 112.82 (+32.02%)
Earnings Date Aug 5, 2024

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2019
Employees 6,133
Stock Exchange NASDAQ
Ticker Symbol BNTX
Full Company Profile

Financial Performance

In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $112.82, which is an increase of 32.02% from the latest price.

Price Target
(32.02% upside)
Analyst Consensus: Buy
Stock Forecasts


Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

Other symbols: PFE
24 days ago - Business Wire

BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

MAINZ, Germany and SHANGHAI, China, June 24, 2024 –  BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Adminis...

27 days ago - GlobeNewsWire

Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?

BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.

Other symbols: PFE
4 weeks ago - Benzinga

US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug

Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer drug.

4 weeks ago - Reuters

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating ...

Other symbols: GMAB
7 weeks ago - Business Wire

New U.S. bird-flu case is first with respiratory symptoms, CDC says

A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.

Other symbols: MRNAPFE
7 weeks ago - Market Watch

BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants

COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.

7 weeks ago - Reuters

BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem

MAINZ, Germany/OSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic partner...

7 weeks ago - GlobeNewsWire

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nas...

7 weeks ago - PRNewsWire

BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at...

2 months ago - GlobeNewsWire

Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term

Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T...

2 months ago - GlobeNewsWire

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the sh...

2 months ago - GlobeNewsWire

BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm

American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine maker shrugged off losses and tumbling sales in the first quarter, g...

2 months ago - Investopedia

BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales

The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.

2 months ago - Barrons

BioNTech says 90% of 2024 revenues will accrue at end of year

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the...

2 months ago - Reuters

BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-...

2 months ago - GlobeNewsWire

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1...

Other symbols: GSKPFE
3 months ago - Reuters

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Addit...

3 months ago - GlobeNewsWire

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

MAINZ, Germany, April 7, 2024 -  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-sp...

3 months ago - GlobeNewsWire

BioNTech gets US agency notice over default on COVID vaccine royalties

BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.

4 months ago - Reuters

BioNTech Earnings Fall Short of Estimates. The Stock Is Down.

The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.

4 months ago - Barrons

BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024

BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is bein...

4 months ago - Invezz

BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory

Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations, we...

4 months ago - Market Watch

After earnings plunge, BioNTech pins hopes on cancer drug launches

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards canc...

4 months ago - Reuters

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten ...

4 months ago - GlobeNewsWire